Treatment-related AEs (TRAE) were reported in 90.3% (28/31) of patients, the most common of which occurred in at least 10% of the participants were elevations in levels of aspartate aminotransferase [12 (38.7%)], alanine aminotransferase [11 (35.5%)], conjugated bilirubin [7 (22.6%)], blood bilirubin [7 22.6%)], decreased platelet counts [7 (22.6%)], asthenia [7 (22.6%)], and rash [5 (16.1%)] (Table 4). The gene discussed is GPT; the disease is asthenia.